In a career spanning four decades, Davies spearheaded the cholinergic hypothesis, unlocked secrets of tau, and readily shared antibodies in the field.
Biogen got the go-ahead under the FDA’s accelerated approval pathway, which requires change in a surrogate biomarker and Phase 4 studies to verify a clinical benefit.
Schenk loses two-year battle with pancreatic cancer.
Pancreatic cancer felled the man who led groundbreaking research on astrocytes, oligodendrocytes, and microglia.
As shocked researchers notify each other privately, the Alzforum editors are saddened to inform the community at large that Mark Smith died last Sunday...
Futility analysis predicts failure to reach primary endpoint.
Most observational cohorts are on pause, and many clinical trials have stopped dosing. The long-term effects on the integrity of AD studies are unclear.
After shutting down a Phase 3 program last March, Biogen now says the futility analysis it did was incorrect, and that a new analysis of a larger dataset in fact supports filing for FDA marketing approval next year.
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
Using a collection of isogenic iPSC-derived neurons harboring different familial AD mutations, researchers found that, across the board, the mutations meddled with endosomes via elevated β-CTF.
Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...
Discoverer of ApoE4 risk allele died of a heart attack.
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
It is with deep sadness that we inform the Alzheimer research community of the passing of Anne Cataldo...
Researchers consider the data encouraging, though questions linger about the cognition results. Did regulators mess up the randomization of this trial?